Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 20, 20 December 2023
Open
Access | Article
Treatment of autism spectrum disorder by regulating neurotransmitters and modifying genes
* Author to whom correspondence should be addressed.
Abstract
Autism spectrum disorder (ASD) is a neurological and developmental disorder, which has many underlying causes, making it much more challenging to find an appropriate treatment to cure. It has been found that ASD is related to a wide variety of neurochemical changes, including GABA, oxytocin, and several monoamine neurotransmitters such as dopamine, norepinephrine, and serotonin. Since ASD is heterogeneous, precise technology such as PET, LP, iEEG, rs-fMRIs, and MRS had been emerged to discover the site of illness. It requires a persistent effort since the ASD phenotype is invertible instead of unchanged, which will be explained soon. Until now, only genetic modified virus (rAAV) have so far successfully incorporated with transduction and gene expression in vivo. However, whether the presence of neutralizing circulating antibodies will preclude intravenous administration is unsure. Instead of systemic delivery, intrathecal administration is discovered as a substitute, which can solve the problem and have advanced to a clinical trial. More gene therapies are hypothesized, for instance, using rAAV for gene replacement, ASOs for RNA knockdown, and CRISPR/Cas9 for gene editing. Unfortunately, these gene therapies still have a long way to go to overcome the restrictions. As a result, this research will analyze the different treatments for the ASD.
Keywords
monoamine neurotransmitters, heterogeneous, gene editing
References
1. Allely, C. S., Gillberg, C. and Wilson, P., "Neurobiological abnormalities in the first few years of life in individuals later diagnosed with autism spectrum disorder: a review of recent data," Behavioural neurology 2014, 210780 (2014).
2. Kodak, T. and Bergmann, S., "Autism Spectrum Disorder: Characteristics, Associated Behaviors, and Early Intervention," Pediatric clinics of North America 67, 525–535 (2020)
3. Foxx R. M., "Applied behavior analysis treatment of autism: the state of the art," Child and adolescent psychiatric clinics of North America 17, 821–ix (2008).
4. Zhao, M., Havrilla, J., Peng, J., Drye, M., Fecher, M., Guthrie, W., Tunc, B., Schultz, R., Wang, K. and Zhou, Y., "Development of a phenotype ontology for autism spectrum disorder by natural language processing on electronic health records," Journal of neurodevelopmental disorders 14, 32 (2022).
5. Voss, C., Schwartz, J., Daniels, J., Kline, A., Haber, N., Washington, P., Tariq, Q., Robinson, T. N., Desai, M., Phillips, J. M., Feinstein, C., Winograd, T. and Wall, D. P., "Effect of Wearable Digital Intervention for Improving Socialization in Children With Autism Spectrum Disorder: A Randomized Clinical Trial," JAMA pediatrics 173, 446–454 (2019)
6. Genovese, A. and Butler, M. G., "Clinical Assessment, Genetics, and Treatment Approaches in Autism Spectrum Disorder (ASD)," International journal of molecular sciences 21, 4726 (2020).
7. McCarty, P. J., Pines, A. R., Sussman, B. L., Wyckoff, S. N., Jensen, A., Bunch, R., Boerwinkle, V. L. and Frye, R. E., "Resting State Functional Magnetic Resonance Imaging Elucidates Neurotransmitter Deficiency in Autism Spectrum Disorder," Journal of personalized medicine 11, 969 (2021)
8. Gray S. J., "Gene therapy and neurodevelopmental disorders," Neuropharmacology 68, 136–142 (2013)
9. Schuster, D. J., Dykstra, J. A., Riedl, M. S., Kitto, K. F., Belur, L. R., McIvor, R. S., Elde, R. P., Fairbanks, C. A., and Vulchanova, L., "Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse," Frontiers in neuroanatomy 8, 42 (2014)
10. Kole, R., Krainer, A. R., and Altman, S., "RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nature reviews," Drug discovery 11, 125–140 (2012)
11. Peng, R., Lin, G., and Li, J., "Potential pitfalls of CRISPR/Cas9-mediated genome editing," The FEBS journal 283, 1218–1231 (2016).
12. Staahl, B. T., Benekareddy, M., Coulon-Bainier, C., Banfal, A. A., Floor, S. N., Sabo, J. K., Urnes, C., Munares, G. A., Ghosh, A., and Doudna, J. A., "Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes," Nature biotechnology 35, 431–434 (2017)
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-213-8
- ISBN (Online)
- 978-1-83558-214-5
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/20/20230711
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited